Vitamin D Status and Treatment in ESKD: Links to Improved CKD-MBD Laboratory Parameters in a Real-World Setting
American Journal of Nephrology · 2024
DOI: 10.1159/000541109 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Nephrology, 2024. Verfasst von Rachel M Holden und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Queen's University, Kingston, Ontario, Canada. Hauptthemen laut MEDLINE: Vitamin D Deficiency, Parathyroid Hormone, Renal Dialysis, Kidney Failure, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Introduction
Vitamin D insufficiency is common in patients who receive hemodialysis, yet there is no clear guidance regarding surveillance or treatment. We hypothesized that increasing 25(OH)D3 levels is associated with lower phosphate, parathyroid hormone (PTH), and alkaline phosphatase (ALP).
Methods
Baseline 25(OH)D3 level was measured in all patients receiving in-center hemodialysis in June 2017. Laboratory parameters were measured every 6 (phosphate, calcium) or 12 weeks (25(OH)D3, PTH, ALP) until February 2021. In September 2018, a treatment algorithm of 50,000 IU weekly until sufficient followed by 50,000 IU monthly was suggested. Generalized linear mixed regression models including linear spline effects, a log link function, and random effects were used to examine the impact of increasing 25(OH)D3 levels on calcium, phosphate, ALP, and PTH.
Results
Of 697 participants, 15% and 57% had vitamin D deficiency (25(OH)D3 <25 nmol/L) and insufficiency (between 25 and 74 nmol/L). Incorporating up to 7,272 observations, increasing 25(OH)D3 was associated with significantly decreasing PTH for 25(OH)D3 levels between 25 and 75 nmol/L regardless of vitamin D treatment. In an interaction model, the negative slope between 25(OH)D3 and PTH remained significant beyond 75 nmol/L in the absence of calcitriol. Increasing 25(OH)D3 was associated with significantly decreasing phosphate for 25(OH)D3 levels between 25 and 75 nmol/L regardless of vitamin D treatment and below 25 nmol/L in values of untreated patients. Calcium increased across the spectrum of 25(OH)D3 regardless of vitamin D treatment. Overall, 0.2% of 25(OH)D3 levels exceeded 250 nmol/L and 2.1% of calcium levels exceeded the normal range.
Conclusions
Vitamin D treatment in a real-world setting was safe and associated with lower PTH levels. Whether improved biochemical markers translate to a reduction in clinical endpoints warrants further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Queen's University, Kingston, Ontario, Canada.
- Department of Biomedical and Molecular Science, Queen's University, Kingston, Ontario, Canada.
- Kingston General Health Research Institute, Kingston, Ontario, Canada.
- Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada.
- Division of Endocrinology and Metabolism, Department of Medicine, Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
Zitieren
APA
Holden, R. M., Norman, P. A., Day, A. G., Silver, S. A., Clemens, K. K., & Iliescu, E. (2024). Vitamin D Status and Treatment in ESKD: Links to Improved CKD-MBD Laboratory Parameters in a Real-World Setting. American Journal of Nephrology. https://doi.org/10.1159/000541109
Vancouver
Holden RM, Norman PA, Day AG, Silver SA, Clemens KK, Iliescu E. Vitamin D Status and Treatment in ESKD: Links to Improved CKD-MBD Laboratory Parameters in a Real-World Setting. American Journal of Nephrology. 2024. doi:10.1159/000541109
BibTeX
@article{Holden2024,
author = {Holden, Rachel M and Norman, Patrick A and Day, Andrew G and Silver, Samuel A and Clemens, Kristen K and Iliescu, Eduard},
title = {Vitamin D Status and Treatment in ESKD: Links to Improved CKD-MBD Laboratory Parameters in a Real-World Setting},
journal = {American Journal of Nephrology},
year = {2024},
doi = {10.1159/000541109}
}
EUVIMED